thomas mcnerney  partners home profile team companies news contact offices contact us via email at operationstmpartnerscom connecticut office one stamford plaza  tresser blvd th floor stamford ct   minnesota office  central ave ne  minneapolis mn   âš  thomas mcnerney  partners  all rights reserved thomas mcnerney  partners home profile team companies news contact professionals james thomas alex zisson kathleen tune kristi lacroix james thomaspartner alex zissonadvisor kathleen tuneadvisor kristi lacroixcontroller âš  thomas mcnerney  partners  all rights reserved thomas mcnerney  partners home profile team companies news contact professionals james thomas alex zisson kathleen tune kristi lacroix alex zisson advisoralex was a partner at thomas mcnerney  partners since its first fund was raised in  alex is currently a managing director at hig bioventures he currently serves on the board of directors for clarus therapeutics inc and keystone dental inc alex is a member of the industry advisory board of the childrens tumor foundation and a board member of advanced medical research institute of canada development corporation amricdc which is focused on economic development in northern ontario he is also an advisor for the partnership fund of nyc which manages a bioaccelerator to advance local health care research and is on the life sciences council for springboard enterprises a group that assists female entrepreneurs prior to thomas mcnerney he spent  years in the research department at hambrecht  quist and its successor firms chase hq and jpmorgan hq during his tenure at hq alex led research teams covering the biotechnology specialty pharmaceutical largecap pharmaceutical drug delivery and diagnostic industries after the merger of chase hq and jpmorgan he became the firms health care strategist he was named twice in the wall street journals allstar analysts survey including during his last year at jpmorgan when he placed in all three categories stock picking  in pharmaceuticals earnings estimate accuracy tied for  and home run hitting  across all industries he graduated magna cum laude from brown university where he was elected to phi beta kappa âš  thomas mcnerney  partners  all rights reserved thomas mcnerney  partners home profile team companies news contact professionals james thomas alex zisson eric aguiar md kathleen tune jason brown phd susan haedt kristi lacroix jason m brown phd partnerjason joined thomas mcnerney  partners in  after spending four years as a member of the investment team at forward ventures where he played an active role in forwardled rounds of investment totaling over  million prior to joining forward jason conducted research in antimicrobial drug discovery and bacterial genomics as a postdoctoral fellow in infectious diseases at johnson  johnson pharmaceutical research and development he is currently a board member of  tioga pharmaceuticals inc jason earned a phd in biology at the university of california san diego where he was a national science foundation fellow and a bs in molecular biology and biochemistry from purdue university âš  thomas mcnerney  partners  all rights reserved thomas mcnerney  partners recent newsarchivevertiflex® home profile team companies news contact recent news archive ethicon announces agreement to acquire torax medical inc                                             february   partners group to acquire pci pharma services a leading global provider of outsourced pharmaceutical services                                                                                                         june   jazz pharmaceuticals and celator pharmaceuticals announce agreement for jazz pharmaceuticals to acquire celator for  per share                                                         may                                                     btg plc acquires galil medical a leader in cryoablation                                                           may   celator announces phase  trial for vyxeos cpx in patients with high risk acute myeloid leukemia demonstrates statistically significant improvement in overall survival march   icalamerican medical association creates new category  code for torax medicals linx procedure to treat gastroesophageal reflux disease                                                               november   vertiflex® announces two significant reimbursement milestones to expand market opportunity for superion interspinous spacer vertiflex®                                                     november   celator r pharmaceuticals announces positive induction response results from phase  study of cpx in patients with highrisk secondary acute  myeloid leukemia june   tioga pharmnaceuticals announces initiation of phase  clinical study of asimadoline in patients with pruritus associated with atopic dermatitis june   vertiflexr inc announces fda pma approval for the superionr interspinous spacer may   teva reinforces leadership position in cns with acquisition of auspex march   boston scientific receives fda approval for watchman tm left atrial appendage closure device march   vertiflexr inc announces fda advisory panel support for the superionr interspinous spacer february   invitae announces pricing of initial public offering of common stock february   cas medical systems announces pricing of public offering of common stock february   auspex pharmaceuticals completes enrollment in a pivotal clinical trial of  in tardive dyskinesia february   auspex announces pricing of follow on offering january   celatorr pharmaceuticals receives fda fast track designation for cpx for the treatment of elderly patients with secondary acute myeloid leukemia january   auspex pharmaceuticals receives fda orphan drug designation of sd for treatment of tourette syndrome in the pediatric population january   auspex pharmaceuticals announces sd program for the potential treatment of parkinsons disease and related movement disorders january   casmed appoints paul molloy to its board of directors january   auspex announces topline results from registration trial of sd for chorea associated with huntingtons disease december   auspex pharmaceuticals receives fda orphan drug designation of sd for treatment of huntingtons disease november   celatorr pharmaceuticals announces phase  clinical study of cpx achieved target enrollment in high risk secondary acute myeloid leukemia october   invitae completes  million series f financing october   pfizer completes acquisition of innopharma september   pci announces definitive agreement to acquire penn pharma july   clarus therapeutics expands board of directors with appointment of two pharmaceutical industry veterans july   auspex pharmaceuticals initiates pivotal phase  clinical trial for sd in tardive dyskinesia july   pfizer to acquire innopharma inc july   auspex pharmaceuticals announces data from interim analysis of archd switch trial demonstrating clinical activity of sd june   clarus therapeutics secures  million in financing june   celatorr pharmaceuticals announces publication of positive phase  data with cpx in acute myeloid leukemia patients  may   casmed receives fda approval for foresite elite in noncerebral tissue may   auspex pharmaceuticals added to the russell ® index march   auspex announces completion of public offering and exercise in full of underwriters overallotment option february   auspex announces pricing of initial public offering february   vertiflexr inc announces decision by the centers for medicare  medicaid services january   clarus therapeutics submits new drug application for rextoro formerly clr for the treatment of low testosterone  january   celatorr pharmaceuticals reaches  enrollment for cpx phase  study  january   auspex raises  million and appoints industry veteran gerald proehl to its board of directors january     thomas mcnerney  partners  all rights reserved insider trading  thomas mcnerney  partners ii llc  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  thomas mcnerney  partners ii llc select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm cas medical systems inc casm thomas mcnerney  partners ii lpthomas mcnerney  partners ii llctmp nominee ii llctmp associates ii lp owner    directindirect view sale  pm auspex pharmaceuticals inc aspx thomas mcnerney  partners ii llcthomas mcnerney  partners ii lptmp associates ii lptmp nominee ii llcdirector owner    indirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing equity swap  am nana auspex pharmaceuticals inc aspx thomas mcnerney  partners ii llcthomas mcnerney  partners ii lptmp associates ii lptmp nominee ii llcdirector owner   indirect view conversion  pm nana invitae corp nvta aguiar ericthomas mcnerney  partners ii lptmp associates ii lptmp nominee ii llcthomas mcnerney  partners ii llcdirector owner   indirect view conversion  pm nana invitae corp nvta aguiar ericthomas mcnerney  partners ii lptmp associates ii lptmp nominee ii llcthomas mcnerney  partners ii llcdirector owner   indirect view conversion  pm nana invitae corp nvta aguiar ericthomas mcnerney  partners ii lptmp associates ii lptmp nominee ii llcthomas mcnerney  partners ii llcdirector owner   indirect view conversion  pm nana invitae corp nvta aguiar ericthomas mcnerney  partners ii lptmp associates ii lptmp nominee ii llcthomas mcnerney  partners ii llcdirector owner   indirect view conversion  pm nana invitae corp nvta aguiar ericthomas mcnerney  partners ii lptmp associates ii lptmp nominee ii llcthomas mcnerney  partners ii llcdirector owner   indirect view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  thomas mcnerney  partners ii lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors thomas mcnerney  partners ii lp check out list of companies and businesses related to thomas mcnerney  partners ii lp find out thomas mcnerney  partners ii lp address and contact details view other people related to thomas mcnerney  partners ii lp  coworkers colleagues companions etc address  south seventh street suite  minneapolis  mn companies related to thomas mcnerney  partners ii lp cikcompany namepositioncompany addressauspex pharmaceuticals inc n torrey pines court suite  la jolla  thomas mcnerney  partners ii lp on the web persons related to thomas mcnerney  partners ii lp  auspex pharmaceuticals incnamepositioncitysommer andreasvistasommer andreasla jollasommer andreasla jollasommers andreasvistalynn dorsey bleildirector san diegobharat m chowrirachief operating officer boulderbharat m chowrirachief operating officer san diegobharat m chowrirachief operating officer san diegocmea ventures vii lp owner san franciscocmea ventures vii parallel lpsan franciscostamler davidla jollastamler davidla jollacollier davidsan franciscocollier davidsan franciscocollier davidsan franciscodeerfield capital lp et alnew yorkdeerfield international master fund lpnew yorkmanagement co deerfieldnew yorkmanagement co ny deerfielddeerfield mgmt lpnew yorkdeerfield partners lpnew yorkdeerfield partners lpnew yorkdeerfield private design fund ii lpnew yorkdeerfield private design international ii lproad town tortoladeerfield private design international ii lpnew yorkdeerfield private design international ii ltdnew yorkdeerfield special situations fund lpnew yorkdeerfield special situations international master fund lpnew yorkrodney a fergusondirector rodney a fergusondirector campbellrodney a fergusonsan diegojames e flynn owner new yorkaggarwal gauravla jollar scott greerdirector r scott greerdirector san diegor scott greerdirector san diegofritz lawrencela jollafritz lawrencela jollagrey michaelvistapanorama capital lp owner campbellshah pratiksan franciscoshah pratikla jollashah pratikvistashah pratikla jollagerald t proehldirector san diegogerald t proehldirector san diegogerald t proehldirector san diegogilmore rvistaferguson rodla jollanewbold ronvistasamuel r sakschief development officer palo altosamuel r sakschief development officer san diegosamuel r sakschief development officer san diegosachs samvistasaks samuelvistasaks samuella jollasaks samuella jollasepehr sarshardirector san diegojohn p schmidchief financial officer san diegojohn p schmidsan diegojohn p schmidchief financial officer san diegophillip m schneiderdirector carlsbadphillip m schneiderdirector san diegosarshar sepvistasarshar sepla jollasharshar sepla jollasarshar sepehrvistasarshar sepehrla jollapratik shahpresident and ceo minneapolispratik shahpresident and ceo san diegopratik shahpresident and ceo san diegoandreas sommersan diegodavid a stamlerchief medical officer santa claradavid a stamlersan diegodavid a stamlerchief medical officer la jollagant thomasvistathomas mcnerney  partners ii llcdirector minneapolisthomas mcnerney  partners ii llcdirector minneapolisthomas mcnerney  partners ii llcdirector minneapolistmp associates ii lpminneapolistmp associates ii lpminneapolistmp associates ii lpminneapolistmp nominee ii llcminneapolistmp nominee ii llcminneapolistmp nominee ii llcminneapolisalex zissondirector minneapolisalex zissondirector san diegoalex zissondirector minneapolisalex zissondirector minneapolis potentially same personnamecitycountrythomas mcnerney  partners ii lpminneapolismnthomas mcnerney  partners ii lpminneapolismnthomas mcnerney  partners ii lpminneapolismnthomas mcnerney  partners ii lpminneapolismnthomas mcnerney  partners ii lpminneapolismnthomas mcnerney  partners ii lpstamfordctthomas mcnerney  partners ii lpminnepolismnthomas mcnerney  partners ii lpstamfordct thomas mcnerney  partners ii lp private company information  bloomberg july    pm et capital markets company overview of thomas mcnerney  partners ii lp snapshot people company overview thomas mcnerney  partners ii lp specializes in incubation and investments in startup mid venture late venture pipes and bridge financing it focuses on investments in preclinical and clinical stages the fund also invests in commercialization asset acquisitions restructuring and consolidation it prefers to invest in the healthcare sector with a focus on biotechnology pharmaceuticals medical devices life sciences and medical technology the fund invests between  million and  million in each company it seeks to be a lead investor in its portfolio companies one stamford plaza tresser boulevardsuite stamford ct united statesfounded in  phone  fax  key executives for thomas mcnerney  partners ii lp mr james e thomas msc partner age  compensation as of fiscal year  similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact thomas mcnerney  partners ii lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close thomas mcnerney  partners ii lp ceo and executives  bloomberg july    pm et capital markets company overview of thomas mcnerney  partners ii lp snapshotpeople  overviewboard memberscommittees key executives for thomas mcnerney  partners ii lp nameboard relationshipstitleagejames e thomas msc relationshipspartner thomas mcnerney  partners ii lp board members nameboard relationshipsprimary companyagethere is no board members data available thomas mcnerney  partners ii lp executive committees committee namechairpersonboard relationshipsmembersthere is no committee data available data is at least as current as the most recent definitive proxy request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup ceo compensation in this industry  industry range industry executive changesthere is no executive change data availablesponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact thomas mcnerney  partners ii lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close secgems thomas mcnerney  partners ii lp data feeds now available excel  csv  java  python etc database learn more thomas mcnerney  partners ii lp info ownership filings ←   → ownership filings    of   total  filing date  submission nc form sc ga schedule filed to report acquisition of beneficial ownership of  or more of a class of equity securities by passive investors and institutions filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer ocera therapeutics inc ocrx reporting owner thomas mcnerney  partners lp   owner  tmp associates lp   owner  tmp nominee llc   owner  thomas mcnerney  partners llc   owner  thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  thomas mcnerney  partners ii llc   owner  thomas james e   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer invitae corp nvta reporting owner thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  thomas mcnerney  partners ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own filing date  submission nc form sc ga schedule filed to report acquisition of beneficial ownership of  or more of a class of equity securities by passive investors and institutions filing date  submission nc form sc g schedule filed to report acquisition of beneficial ownership of  or more of a class of equity securities by passive investors and institutions filing date  submission nc form sc da acquisition of beneficial ownership of  or more of any class of equity securities includes buy  acquire  sell  dispose  or more incl takeovers change of control filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer auspex pharmaceuticals inc aspx reporting owner thomas mcnerney  partners ii llc   owner director  thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocku  disp in a change of control transfalsedisee footnote filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer invitae corp nvta reporting owner aguiar eric   owner director  thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  thomas mcnerney  partners ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stockc  deriv security convfalseaisee footnote derriv transseries a preferred stockc  deriv security convfalsedcommon stockisee footnote derriv transseries c preferred stockc  deriv security convfalsedcommon stockisee footnote derriv transseries e preferred stockc  deriv security convfalsedcommon stockisee footnote derriv transseries f preferred stockc  deriv security convfalsedcommon stockisee footnote filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer cas medical systems inc casm reporting owner thomas mcnerney  partners ii lp   owner  thomas mcnerney  partners ii llc   owner  tmp nominee ii llc   owner  tmp associates ii lp   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stockp  open market or private purchasefalsead nonderriv transcommon stockp  open market or private purchasefalseaiby tmp nominee ii llc nonderriv transcommon stockp  open market or private purchasefalseaiby tmp associates ii lp filing date  submission nc form sc da acquisition of beneficial ownership of  or more of any class of equity securities includes buy  acquire  sell  dispose  or more incl takeovers change of control filing date  submission nc form  ownership initial statement of beneficial ownership of securities insider trading  directors officers significant shareholders  issuer invitae corp nvta reporting owner aguiar eric   owner director  thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  thomas mcnerney  partners ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own derriv holdingseries a preferred stockcommon stockisee footnote derriv holdingseries c preferred stockcommon stockisee footnote derriv holdingseries e preferred stockcommon stockisee footnote derriv holdingseries f preferred stockcommon stockisee footnote filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer auspex pharmaceuticals inc aspx reporting owner thomas mcnerney  partners ii llc   owner director  thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedisee footnote filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer auspex pharmaceuticals inc aspx reporting owner thomas mcnerney  partners ii llc   owner director  thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stockm  exer or conv of deriv security exemptedfalseaisee footnote nonderriv transcommon stockd  disp to issuerfalsedisee footnote derriv transcommon stock warrantm  exer or conv of deriv security exemptedfalsedcommon stockisee footnote derriv transcommon stock warrantm  exer or conv of deriv security exemptedfalsedcommon stockisee footnote derriv transcommon stock warrantm  exer or conv of deriv security exemptedfalsedcommon stockisee footnote filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer auspex pharmaceuticals inc aspx reporting owner thomas mcnerney  partners ii llc   owner director  thomas mcnerney  partners ii lp   owner director  tmp associates ii lp   owner director  tmp nominee ii llc   owner director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stockm  exer or conv of deriv security exemptedfalseaisee footnote nonderriv transcommon stockd  disp to issuerfalsedisee footnote derriv transcommon stock warrentm  exer or conv of deriv security exemptedfalsedcommon stockisee footnote filing date  submission nc form a ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer auspex pharmaceuticals inc aspx reporting owner thomas mcnerney  partners ii lp   owner director  tmp associates ii lp   owner director  tmp nominee ii llc   owner director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stockm  exer or conv of deriv security exemptedfalseaisee footnote nonderriv transcommon stockd  disp to issuerfalsedisee footnote derriv transcommon stock warrantm  exer or conv of deriv security exemptedfalsedcommon stockisee footnote filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer auspex pharmaceuticals inc aspx reporting owner thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stockx  exer inmoney  atmoney deriva securityfalseaisee footnote nonderriv transcommon stocks  open market or private salefalsedisee footnote derriv transcommon stock warrantx  exer inmoney  atmoney deriva securityfalsedcommon stockisee footnote filing date  submission nc form sc d acquisition of beneficial ownership of  or more of any class of equity securities includes buy  acquire  sell  dispose  or more incl takeovers change of control filing date  submission nc form sc g schedule filed to report acquisition of beneficial ownership of  or more of a class of equity securities by passive investors and institutions filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer auspex pharmaceuticals inc aspx reporting owner thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stockc  deriv security convfalseaisee footnote nonderriv transcommon stockp  open market or private purchasefalseaisee footnote derriv transseries b convertible preferred stockc  deriv security convfalsedcommon stockisee footnote derriv transseries c convertible preferred stockc  deriv security convfalsedcommon stockisee footnote derriv transseries d convertible preferred stockc  deriv security convfalsedcommon stockisee footnote derriv transseries e convertible preferred stockc  deriv security convfalsedcommon stockisee footnote derriv transpreferred stock warrantc  deriv security convfalsedseries c preferred stockisee footnote derriv transcommon stock warrantc  deriv security convfalseacommon stockisee footnote derriv transpreferred stock warrantc  deriv security convfalsedseries c preferred stockisee footnote derriv transcommon stock warrantc  deriv security convfalseacommon stockisee footnote derriv transpreferred stock warrantc  deriv security convfalsedseries c preferred stockisee footnote derriv transcommon stock warrantc  deriv security convfalseacommon stockisee footnote derriv transpreferred stock warrantc  deriv security convfalsedseries d preferred stockisee footnote derriv transcommon stock warrantc  deriv security convfalseacommon stockisee footnote derriv transpreferred stock warrantc  deriv security convfalsedseries d preferred stockisee footnote derriv transcommon stock warrantc  deriv security convfalseacommon stockisee footnote filing date  submission nc form  ownership initial statement of beneficial ownership of securities insider trading  directors officers significant shareholders  issuer auspex pharmaceuticals inc aspx reporting owner thomas mcnerney  partners ii lp   owner  tmp associates ii lp   owner  tmp nominee ii llc   owner  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own derriv holdingseries b convertible preferred stockcommon stockisee footnote derriv holdingseries c convertible preferred stockcommon stockisee footnote derriv holdingseries d convertible preferred stockcommon stockisee footnote derriv holdingseries e convertible preferred stockcommon stockisee footnote derriv holdingwarrants to purchase series c convertible preferred stockseries c convertible preferred stockisee footnote derriv holdingwarrants to purchase series c convertible preferred stockseries c convertible preferred stockisee footnote derriv holdingwarrants to purchase series c convertible preferred stockseries c convertible preferred stockisee footnote derriv holdingwarrants to purchase series d convertible preferred stockseries d convertible preferred stockisee footnote derriv holdingwarrants to purchase series d convertible preferred stockseries d convertible preferred stockisee footnote ←   → db bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version thomas mcnerney  partners ii lp  form  insider transactions × hey there you need to be logged in to do thatno account no sweat…go get started for free once you have your account you can follow companies and start getting email alerts signup login youll love having an account follow companies easily see and explore all your favorites in one place receive alerts get free alerts on as many companies as you want not now get started thomas mcnerney  partners ii lp insider transactions according to sec form  filings cas medical systems inc  filings  auspex pharmaceuticals  filings  ocera therapeutics inc  filings  sign up to get alerts when thomas mcnerney  partners ii lp files a form  get started recent filings  sec form  shares total dollar amount average transaction codes p s a d f i m c e h o x g l w z j k u these are some powerful tools our intelligent investors subscription offers some of the most advanced tools available to help you find signals in the noise upgrade your account to unleash stocktrots full potenial start with a free account advanced basic open market only transaction sizeshares hey there how can we make this page better   send   sign up for free and get  credit towards a premium account limited time only microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft thomas mcnerney  partners   home profile team companies news contact ethicon announces agreement to acquire torax medical inc                                                                                                    partners group to acquire pci pharma services a leading global provider of oursourced pharmaceutical services                                                                                                    jazz pharmaceuticals and celator pharmaceuticals announce agreement for jazz pharmaceuticals to acquire celator for  per share                                                                                               thomas mcnerney  partners is a health care venture firm that invests in life science and medical technology companies at all stages of development the thomas mcnerney  partners team has significant experience in helping entrepreneurs start companies in providing growth capital to emerging companies and in undertaking restructuring transactions such as spinouts rollups and recapitalizations imagesfinalswf imagesfinalswf â  thomas mcnerney  partners  all rights reserved  site by impend thomas mcnerney  partners home profile team companies news contact recent news archive locus development inc merges with invitae division of genomic health san francisco ca august    genomic health nasdaq ghdx merged its invitae division into locus development inc a thomas mcnerney  partners ii lp portfolio company san francisco cabased locus was founded in  to consolidate the genetic testing market and enable practicing clinicians to interpret patientspecific genomic sequence data the company has developed a panel of tests to detect a broad spectrum of the known genetic mutations and has built a fully functional laboratory to process patient samples randy scott the founder and prior ceo and chairman of genomic health will become ceo and chairman of the combined entity which will retain the invitae name randy has successfully built multibillion dollar companies twice before in his career he has been a board member of locus since  and his passion for the company’s mission and technology drove him to want to lead this combined entity locus’ founding team and employees will remain with the merged company invitae will continue its focus on next generation sequencing for the clinical diagnostics market in fact newly independent invitae already has a significant head start in this rapidly growing segment of the market this transaction expands locus’ product offering to over  genetic conditions in its current testing panel representing the majority of generic tests performed today additionally it brings on board the commercial expertise and experience of randy scott and his team at a critical time for the company having received its clia clearance in may  making locus commercialready thomas mcnerney  partners home profile team companies news contact professionals james thomas alex zisson eric aguiar md kathleen tune jason brown phd susan haedt kristi lacroix eric aguiar md advisoreric was a partner at thomas mcnerney  partners from  to  prior to joining thomas mcnerney he was a managing director of healthcare ventures a health care focused venture capital firm from  eric is currently a partner at aisling capital eric currently sits on the board of invitae corporation formerly locus development inc his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson eric was ceo of genovo inc acquired by targeted genetics a biopharmaceuticals company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals eric was a vice president and managing director of philadelphia ventures from  to  he is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations eric received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar eric was also a luce fellow and is a chartered financial analyst âš  thomas mcnerney  partners  all rights reserved